2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3478 ETNK1 genetic variants define a favorable-risk subset of acute myeloid leukemia: An international multicenter study

Steven Tessier, MD MS, Joy Nakitandwe, PhD, MS2, Najla Al Ali, MS3, Michael Trinh4, Amer M. Zeidan, MD5, Nikansha Kumar, MD6, Diletta Fontana, PhD7, Hailong Zhang, PhD8, Shihan He, PhD9, Pawel Mroz, MD, PhD10, Siddhartha Sen, MD, PhD11, David Sallman, MD12, Eric Padron, MD13, Zhuoer Xie, MD,MS14, James Foran, FRCPC15, Cecilia Arana Yi, M.D.16, David Bosler, MD17, Wen Shuai, MD18, Clifford Csizmar, M.D., Ph.D.19, Jayant Asthana, PhD20, Hassan B Alkhateeb, M.D.21, Rong He, MD22, Mithun Shah, MD, PhD23, Mrinal M. Patnaik, MD, MBBS24, Carlo Gambacorti-Passerini, MD25, Rocco Piazza, MD, PhD26, Ismail Elbaz Younes, MD27, Devendra Hiwase I, Consultant Haematologist28, Alexa Siddon, MD29, Andrew M Brunner, MD30, C. Cameron Yin, MD, PhD31, Rami Komrokji, MD32, Hetty Carraway, MD, MBA33, Aref Al-Kali, M.D.34
1 Mayo Clinic, Rochester, Minnesota, United States
2 Diagnostics Institute, Cleveland Clinic, Cleveland, Ohio, United States
3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut, United States
6 Royal Adelaide Hospital, Central Local Health Network, Adelaide, SA, Australia
7 University of Milano-Bicocca, Monza, Italy
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Jacksonville, Florida, United States
10 University of Minnesota, Minneapolis, Minnesota, United States
11 University of Minnesota, Minneapolis, Minnesota, United States
12 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
15 Mayo Clinic, Jacksonville, Florida, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 Diagnostics Institute, Cleveland Clinic, Cleveland, Ohio, United States
18 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 University of Milano-Bicocca, Monza, Italy
26 University of Milano-Bicocca, Monza, Italy
27 University of Minnesota, Minneapolis, Minnesota, United States
28 Royal Adelaide Hospital, Central Local Health Network, Adelaide, SA, Australia
29 Yale School of Medicine, Yale Cancer Center, New Haven, Connecticut, United States
30 Massachusetts General Hospital, Boston, Massachusetts, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
33 Cleveland Clinic, Cleveland, Ohio, United States
34 Mayo Clinic, Rochester, Minnesota, United States

Introduction: ETNK1 encodes ethanolamine kinase 1, the rate-limiting enzyme of the phosphatidylethanolamine biosynthesis pathway. Recurrent somatic ETNK1 genetic variants (ETNK1MUT) occurring in a kinase domain hotspot (N244, H243, G245) have been reported in small single-institution studies of myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasm (MDS/MPN), and acute myeloid leukemia (AML), but their co-mutation patterns, clonal hierarchy, and prognostic significance across the spectrum of myeloid neoplasms have not been established.

Methods: We identified patients with ETNK1MUT detected by next-generation sequencing from 9 institutions: Mayo Clinic (Minnesota, Florida, Arizona), Massachusetts General Hospital, Yale University, Moffitt Cancer Center, Cleveland Clinic, MD Anderson Cancer Center, University of Milano Bicocca, University of Adelaide, and University of Minnesota. All variants were independently reviewed by 2 genetic variant scientists and 1 hematopathologist, and classified per American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) criteria as pathogenic (P), likely pathogenic (LP), or variant of uncertain significance (VUS). Diagnoses were assigned per World Health Organization 2022 classification. Clinical, cytogenetic, and co-mutation data were retrospectively abstracted, and overall survival (OS) was measured by Kaplan-Meier and Cox analysis with comparison to Mayo Clinic ETNK1-wildtype (ETNK1WT) consecutive cohorts using Prism v11.0.2 and BlueSky Statistics v10.3.4.

Results: We identified 241 ETNK1 variants in 236 ETNK1MUT patients, with 20 distinct ETNK1MUT. Among 241 ETNK1MUT, 186 were P (77%), 33 LP (14%), and 22 VUS (9%). Variants clustered predominantly at N244 (N244S, n=180, 75% of variants), with a second hotspot at K378N (VUS, n=13). Diagnoses at ETNK1MUT detection included MDS (43%), MDS/MPN (25%, predominantly chronic myelomonocytic leukemia [CMML], 3% atypical chronic myeloid leukemia), AML (17%), MPN (10%), and clonal cytopenia/hematopoiesis of undetermined significance (3%). The most frequent co-mutated genes were ASXL1 (46%), RUNX1 (26%), TET2 (26%), EZH2 (24%), SRSF2 (20%), and U2AF1 (17%). Co-mutation burden was consistently higher in ETNK1MUT MDS, CMML, and AML (all P<0.0001) compared to 662 AML, 503 MDS, and 397 CMML ETNK1WT patients (median 4 vs 2, 5 vs 3, and 6 vs 2, respectively). ETNK1MUT was predominantly subclonal (63%; co-dominant 31%; dominant 6%), with splicing factor, epigenetic regulator, and DNA-damage response co-mutations at generally higher variant allele frequency (VAF) than ETNK1, and transcription factor/RAS/RTK/JAK-STAT signaling mutations at comparable VAF. ETNK1MUT P/LP vs VUS ACMG/AMP classification did not influence OS (P=0.61), and VAF was lower for P (median 24.6%) than LP/VUS variants (median 38%; 44.1%) (P=0.02; 0.05). Karyotype was normal in 55% of patients; structural alterations most often involved chromosomes 7 (14% of patients), 8 (10%), 5 (8%), and 1 (7%). In AML, ETNK1MUT strongly trended toward improved OS (median 50 vs 13.6 months; Gehan-Breslow-Wilcoxon P=0.04, logrank P=0.10), despite that the ETNK1MUT AML cohort was enriched for adverse-risk ELN 2022 criteria compared to ETNK1WT (90% vs 65%, P<0.004). Within this adverse-risk subgroup, ETNK1MUT conferred significant OS benefit (median 50 vs 10 months; P=0.002). Notably, patients with adverse-risk ETNK1MUT AML had OS comparable to that of favorable/intermediate-risk ETNK1WT patients (median 50 vs 39 months, P=0.65). On multivariate Cox analysis including age, cytopenias, karyotype, ELN 2022 risk, intensive chemotherapy, hypomethylating agent/venetoclax, and allogeneic stem cell transplant (alloSCT), ETNK1MUT remained an independent favorable factor of OS (HR 0.54, 95% CI 0.30-0.99, P = 0.04). AlloSCT (41% vs 31%, P=0.88) conferred a marked OS benefit among ETNK1MUT AML patients (median 60.8 vs 19.3 months; P=0.003).

Conclusions: Consistent with a mutator phenotype, ETNK1MUT myeloid neoplasms are heavily co-mutated, with ETNK1MUT typically subclonal to splicing factor, epigenetic, and DNA-damage response mutations by VAF inference. In AML, ETNK1MUT is an independent favorable prognostic marker. These findings, curated by international multicenter collaboration, support the inclusion of ETNK1 in diagnostic and prognostic frameworks for myeloid neoplasms and warrant further mechanistic study of its favorable prognostic association.

Steven Tessier, MD MS: No relevant conflicts of interest to declare.